NewMarket Corp (NEU)
Live price chart, market sentiment, and community perspectives for NewMarket Corp (NYSE: NEU).
Live price chart, market sentiment, and community perspectives for NewMarket Corp (NYSE: NEU).
On our desk, NEU has been a fascinating case of momentum clashing with valuation discipline. Trading near its 52-week high around $889, the stock shows pristine fundamental strength with a Piotroski F-Score of 7/9 and a 25.1% ROE. However, with a forward P/E pushing 34.43 against a trailing 19.13, we are advising clients to proceed with caution despite recent analyst upgrades from Wall Street Zen and Weiss Ratings.
From a quantitative risk perspective, the disconnect between the GF Score of 80/100 and the AI fair value estimates sitting at an 8.4% discount creates a challenging entry point. A PEG ratio of 5.64 coupled with a Graham Number benchmark around $457 highlights a stark valuation premium. When modeling downside scenarios, any unexpected compression in segment operating profits could trigger a rapid mean-reversion phase.
Reviewing the 10-Q and Q2 2026 financial metrics, the petroleum additives segment is doing the heavy lifting by maintaining solid operating margins through surcharges, even as net sales dipped slightly over the first half. The Calca acquisition in the specialty materials segment adds interesting growth angles, but the modest top-line contraction across recent quarters suggests volume pressures that aren't fully reflected in the headline EPS of $27.14.
As a risk manager tracking specialty chemical plays, NewMarket's ability to sustain margins amid commodity cost pressures and minor shipment declines is commendable. First-half segment operating profit of $319 million and net income of $251.8 million showcase robust cost discipline. Nevertheless, the debt-to-equity ratio of 0.51 and the rising forward multiple require careful monitoring of macro chemical demand trends for the remainder of 2026.
Watching the recent price action as NEU touched $889.91 with steady institutional interest, market sentiment is definitely leaning toward a 'Hold' consensus as modeled by TrendMatrix, despite recent upgrades to 'Buy'. The strong cash flow supporting ongoing capital returns and debt reduction provides comfort, but at these absolute price levels, the margin for operational error is exceptionally thin.
Explore plasma cleansing, somatic organ swaps, and BCI.